← FDA DRUG APPROVALS

FDA ANDA · ANDA202856

FENOFIBRATE

Sponsor: MYLAN PHARMS INC

APPLICATION
ANDA202856
TYPE
ANDA
ORIGINAL APPROVAL
2012-12-07
LATEST ACTION
2023-03-24
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

FENOFIBRATEPrescription
FENOFIBRATE 48MG · TABLET · ORAL
FENOFIBRATEPrescription
FENOFIBRATE 145MG · TABLET · ORAL

Approval history

2023-03-24Labeling · Supplement 10 · standardAP
2019-08-15Labeling · Supplement 9 · standardAP
2013-07-26Labeling · Supplement 3 · standardAP
2012-12-07UNKNOWN · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →